2.36
-0.20 (-7.81%)
| Previous Close | 2.56 |
| Open | 2.57 |
| Volume | 1,184,230 |
| Avg. Volume (3M) | 694,090 |
| Market Cap | 188,167,776 |
| Price / Earnings (TTM) | 26.22 |
| Price / Earnings (Forward) | 4.29 |
| Price / Sales | 3.15 |
| Price / Book | 3.74 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Profit Margin | 6.54% |
| Operating Margin (TTM) | -40.99% |
| Diluted EPS (TTM) | 0.050 |
| Quarterly Revenue Growth (YOY) | 169.80% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 2.49 |
| Operating Cash Flow (TTM) | 8.67 M |
| Levered Free Cash Flow (TTM) | -3.29 M |
| Return on Assets (TTM) | 3.53% |
| Return on Equity (TTM) | 10.42% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 10.39% |
| % Held by Institutions | 10.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Stratos Wealth Partners, Ltd. | 30 Jun 2025 | 350,000 |
| Evergreen Capital Management Llc | 30 Jun 2025 | 171,338 |
| Diametric Capital, Lp | 30 Jun 2025 | 143,272 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 16 Sep 2025 | Announcement | Presenting at the Investor Summit Q3 2025 on September 16; Watch the Live Stream for Free |
| 11 Sep 2025 | Announcement | Protalix BioTherapeutics to Present at Investor Summit Virtual |
| 02 Sep 2025 | Announcement | Protalix BioTherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference |
| 14 Aug 2025 | Announcement | Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results |
| 07 Aug 2025 | Announcement | Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 |
| 21 Jul 2025 | Announcement | Protalix BioTherapeutics Appoints Gilad Mamlok as its New Senior Vice President and Chief Financial Officer |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |